About Jonathan Rich
Form D filings for Intrommune Therapeutics in 2024 list Jonathan Rich as director.
Jonathan Rich first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Jonathan Rich in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Jonathan Rich works with at each company, as listed on that company's latest Form D.
Intrommune Therapeutics, Inc. · Form D, Jan 22, 2024
EB
Erick Berglund
Director
HP
Hemanshu Pandya
Director
MN
Michael Nelson
President and director
WR
William Reisacher
Director